Quest Diagnostics now offers the Multiple Myeloma, Daratumumab-Specific, Immunofixation test for your multiple myeloma patients on Daratumumab

Quest Diagnostics has launched a FDA-modified, Multiple Myeloma, Daratumumab-Specific, Immunofixation test, detected by a gel shift method that discriminates between endogenous myeloma protein and daratumumab, so the patient’s assessment of the M protein band is made easier.

The Multiple Myeloma, Daratumumab-Specific, Immunofixation test (NTC 94514), should be considered for multiple myeloma patients treated with daratumumab to rule out monoclonal antibody interference.

DARZALEX® (daratumumab; Janssen Biotech) is a human monoclonal antibody that binds to CD38, a protein expressed at low levels in immune white blood cells and in particularly high levels in plasma cells.

If you have patients on daratumumab that require testing, this test can avoid unnecessary follow-up testing and allow more accurate interpretation of depth of response to treatment.

This test is available at Quest’s Nichols Institute, San Juan Capistrano, California.

Click here to download the Multiple Myeloma white paper.